An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Apalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Aragon Pharmaceuticals
- 26 May 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2016 Planned number of patients changed from 44 to 45.
- 21 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2016.